All In Biotech

Drug Trial Radar · NCT04366648

Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor

Study on the Safety, Tolerability and Pharmacokinetics of Single and Multiple Administration of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor

Last checked: Nov 20, 2026Latest source record: Sep 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

May 4, 2018

Primary completion

Mar 31, 2021

Study completion Mar 31, 2021

Sponsor

Lead sponsor
JenKem Technology Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 29, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to evaluate the safety and tolerability of injectable PEG-Irinotecan in patients with malignant solid tumors

Conditions

  • Solid Tumor

Interventions

  • JK-1201IDrug

    malignant solid tumor that has been confirmed by histopathology and/or cytology

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary outcome 1Time frame: 21 days
  2. Primary outcome 2Time frame: 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The fifth medical center of PLA general hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.